Of note, post-treatment with intravenous BAY60-6583 (1 mg/kg) reduces lesion volume in the absence or presence of tPA (10 mg/kg) and attenuates brain swelling, blood–brain barrier disruption, and tPA-exacerbated hemorrhagic transformation (HT) at 24 h after ischemia induced by transient (2 h) middle cerebral artery occlusion (tMCAo) [74]. This evidence concerns the gene PLAT and ischemia.